# Opioid and cannabinoid combinations in laboratory and clinical pain

> **NIH NIH R01** · JOHNS HOPKINS UNIVERSITY · 2020 · $747,430

## Abstract

This laboratory study will evaluate whether a cannabinoid enhances the analgesic efficacy of an opioid in a
clinical sample of chronic pain patients, laying the foundation for a larger clinical trial evaluating the utility of
cannabinoids as potentially opioid-sparing adjuvants to chronic opioid therapy for pain. Heightened CNS
processing, or central sensitization (CS), occurs across numerous chronic pain conditions and is an important
treatment target in its own right. While cannabinoids show initial promise as treatments or adjuncts for some
chronic pain conditions and pre-clinical data suggest effects on CS, little is known about the degree to which
combining cannabinoids with opioids alleviates CS-mediated chronic pain. We propose a within-subject, single
exposure, double-blind, placebo-controlled, human laboratory investigation of the extent to which a
cannabinoid enhances opioid analgesia in a model chronic pain population (e.g., patients with knee
osteoarthritis). Human laboratory studies are an ideal method for this initial evaluation because they provide
the opportunity to tightly control study drug dosing and afford high sensitivity of measurements, and enable
tight control of confounding variables that may otherwise exist in clinical treatment populations and could
differentially impact outcomes. This approach will minimize the number of participants needed to determine
whether a positive signal exists while permitting rigorous and elegant evaluation of the study aims. Primary
study outcomes will include measures of clinical pain and central sensitization, physical function, drug effects
(e.g., abuse liability, adverse events, cognitive performance), and pharmacokinetic analyses. The Aims will
examine the magnitude and duration of cannabinoid/opioid combination in reducing clinical pain and central
sensitization; the effects on physical functioning, adverse events and indices of abuse liability; and the
pharmacokinetic and pharmacodynamics profiles for the individual and combined drugs. This study will provide
the most systematic and rigorous evaluation of the potential for cannabinoids to enhance analgesic effects of
opioids in human subjects to date, and will do so in a relevant and generalizable clinical pain population who
has CS, which makes these results more directly relevant compared to studies conducted in healthy
populations. These findings will be critical to informing the efficacy and safety profile for the advancement of
opioid/cannabinoid combination regimens to clinical trials with chronic pain patients.

## Key facts

- **NIH application ID:** 9686723
- **Project number:** 5R01DA042751-03
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Claudia Michelle Campbell
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $747,430
- **Award type:** 5
- **Project period:** 2017-05-15 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9686723

## Citation

> US National Institutes of Health, RePORTER application 9686723, Opioid and cannabinoid combinations in laboratory and clinical pain (5R01DA042751-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9686723. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*